Business
Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth
Michelle Robertson joins as Chief Financial Officer Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Michelle Robertson joins as Chief Financial Officer\n Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Michelle Robertson as the Company’s Chief Financial Officer, and the appointment of Harry Gill in the newly created role of Senior Vice President, Operations, both effective immediately. “We are thrilled to have Michelle and Harry join Editas and round out our executive team. Michelle’s proven financial acumen, ability to deliver valuable business tools and improve business processes, and strong interpersonal skills will be invaluable in helping drive our growth. Harry is an accomplished leader with significant expertise in quality, plant operations, technical services, and operational excellence,” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine. “This is truly an exciting time to join Editas Medicine. As we advance our pipeline of medicines towards the clinic and to the people who need them, I look forward to working with my colleagues to deliver on our mission for patients and stakeholders,” said Michelle Robertson, Chief Financial Officer, Editas Medicine. “The opportunity to be on the front-line of making this new class of potentially game-changing medicines for people around the world is unique, and I am looking forward to working with the team to build our capabilities and capacity to manufacture and create a supply chain to move several experimental medicines into the clinic,” remarked Harry Gill, Senior Vice President, Operations, Editas Medicine. Collins added, “I look forward to working with Michelle, Harry, and the rest of our strong executive team as progress through the clinical trial for EDIT-101, advance our pipeline, and execute on our bold vision to develop transformative, durable medicines for people living with serious diseases.” Michelle Robertson brings to Editas Medicine more than 25 years of biotech finance and commercial operations management experience. Ms. Robertson joins Editas Medicine from Momenta Pharmaceuticals, Inc., where she held roles of increasing responsibility, most recently serving as Chief Financial Officer. Prior to joining Momenta, Ms. Robertson was Vice...